ArticleCancers2026
Primary Pap Smear Cytological Diagnosis of ASC-US: HR-HPV Genotyping and Follow-Up of HPV-Positive Patients.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ASC-US refers to cytological abnormalities suggestive of squamous intraepithelial lesions (SILs) that are qualitatively or quantitatively insufficient for a definitive diagnosis. In addition to HPV infection, which is the etiological agent of preneoplastic and neoplastic cervical lesions, several other conditions may induce cytological changes classified as ASC-US, including inflammation, atrophy with degeneration, hormonal effects, and technical artifacts. The aim of this study was to evaluate the incidence of primary Pap tests diagnosed as ASC-US that also tested positive for HR-HPV genotypes. In this retrospective study, 6181 primary Pap tests collected between 21 July 2021 and 9 January 2024 from the Roma 2 Local Health District were reviewed. ThinPrep containers (Hologic) were used for liquid-based cytology, allowing both cytological examination and molecular testing for HR-HPV detection. The Anyplex™ II HR HPV Detection assay (Seegene) was used for the identification, by real-time PCR, of 14 HR-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Among the 6181 Pap tests analyzed, 202 cases (3.3%) were diagnosed as ASC-US and subsequently underwent HR-HPV molecular testing. Of these, 107 cases (53.0%) were negative, while 95 (47.0%) were positive for HR-HPV. In HPV-positive samples, single-genotype infections were detected in 65 cases (68.4%), while multiple genotypes were identified in 30 cases (31.6%). A total of 135 HR-HPV genotypes were detected. HPV 16 was identified in nine cases (6.7%), HPV 18 in six (4.4%), HPV 31 in nine (6.7%), HPV 33 in five (3.7%), HPV 35 in two (1.5%), HPV 39 in 10 (7.4%), HPV 45 in four (3.0%), HPV 51 in 20 (14.8%), HPV 52 in seven (5.2%), HPV 56 in 15 (11.1%), HPV 58 in eight (5.9%), HPV 59 in 17 (12.6%), HPV 66 in 12 (8.9%), and HPV 68 in 11 cases (8.1%). Our findings indicate that approximately half of ASC-US diagnoses are associated with HR-HPV infection. Interestingly, the detected viral genotypes mainly belonged to less common HR-HPV strains. HR-HPV testing following an ASC-US cytological diagnosis is essential for colposcopy triage, while extended genotyping enables the monitoring of genotype persistence over time, a key factor in the development of cervical dysplastic and neoplastic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.